5-azacitidine in combination with donor lymphocyte infusions for the treatment of patients with MDS or AML relapsing after allogeneic stem cell transplantation.

被引：2
|
作者：
Czibere, Akos
Graef, Thorsten
Lind, Jens
Gattermann, Norbert
Zohren, Fabian
Fenk, Roland
Haas, Rainer
Kobbe, Guido
机构：
[1] Univ Dusseldorf, Dept Haematol & Oncol, Clin Immunol, D-4000 Dusseldorf, Germany
[2] Harvard Univ, Harvard Inst Med & Stem Cell, Boston, MA 02115 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.5341.5341
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5341
引用
收藏
页码：428B / 428B
页数：1
相关论文
共 50 条
  • [21] Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation
    Oran, B.
    Giralt, S.
    Couriel, D.
    Hosing, C.
    Shpall, E. J.
    de Meis, E.
    Khouri, I. F.
    Qazilbash, M.
    Anderlini, P.
    Kebriaei, P.
    Popat, U.
    Carrasco-Yalan, A.
    Champlin, R. E.
    de Lima, M.
    LEUKEMIA, 2007, 21 (12) : 2540 - 2544
  • [22] Efficacy of donor lymphocyte infusions in myelodysplastic syndromes relapsing after allogeneic stem cell transplantation: Importance of karyotype.
    Selleslag, DLD
    Nollet, F
    Billiet, J
    van Droogenbroeck, J
    van Hoof, A
    van Eygen, K
    Hidajat, M
    Criel, A
    BLOOD, 2004, 104 (11) : 406A - 406A
  • [23] Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)
    Schroeder, Thomas
    Rautenberg, Christina
    Christopeit, Max
    Stelljes, Matthias
    Schmidt, Eva
    Klein, Stefan
    Scheid, Christof
    Beelen, Dietrich W.
    Nachtkamp, Kathrin
    Haas, Rainer
    Germing, Ulrich
    Kroger, Nicolaus
    Kobbe, Guido
    BLOOD, 2017, 130
  • [24] Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.
    Vaughn, Jennifer
    Storer, Barry
    Mielcarek, Marco
    Warren, Edus H., III
    Martin, Paul J.
    Sandmaier, Brenda M.
    Estey, Elihu H.
    Storb, Rainer
    Deeg, H. Joachim
    Scott, Bart Lee
    BLOOD, 2010, 116 (21) : 551 - 551
  • [25] Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with donor lymphocyte transfusion - A retrospective analysis of EBMT results.
    Schmid, C
    Alessandrino, E
    Bunjes, D
    Ferrant, A
    Frassoni, F
    Gluckman, E
    Holler, E
    Jacobsen, N
    Ljungman, P
    Schattenberg, A
    Verdonck, L
    Kolb, HJ
    BLOOD, 2000, 96 (11) : 477A - 477A
  • [26] Efficacy of 5-azacitidine in treating imminent relapse of patients with high-risk MDS or AML and minimal residual disease after allogeneic stem cell transplantation: results of the RELAZA trial
    Platzbecker, U.
    Wermke, M.
    Radke, J.
    Kiani, A.
    Seltmann, F.
    Oelschlaegel, U.
    Roellig, C.
    Mohr, B.
    von Bonin, M.
    Schetelig, J.
    Ehninger, G.
    Bornhaeuser, M.
    Thiede, C.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S79 - S79
  • [27] Donor Lymphocyte Infusions and Rituximab Are An Effective Treatment Strategy for B-Cell Lymphoma Relapsing After Reduced Intensity Allogeneic Stem Cell Transplantation
    Spina, Francesco
    Patriarca, Francesca
    Farina, Lucia
    Montefusco, Vittorio
    Dodero, Anna
    Carniti, Cristiana
    Fanin, Renato
    Corradini, Paolo
    BLOOD, 2009, 114 (22) : 1283 - 1284
  • [28] SIRPB1: BIOMARKER OF RESPONSE TO 5-AZACITIDINE TREATMENT IN MDS AND AML PATIENTS
    Guadagnuolo, V.
    Papayannidis, C.
    Iacobucci, I.
    Fontana, M. C.
    Simonetti, G.
    Padella, A.
    Imbrogno, E.
    Paolini, S.
    Abbenante, M. C.
    Parisi, S.
    Sartor, C.
    Ottaviani, E.
    Ferrari, A.
    Delledonne, M.
    Malagola, M.
    Fili, C.
    Russo, D.
    Cavo, M.
    Martinelli, G.
    HAEMATOLOGICA, 2015, 100 : 479 - 480
  • [29] Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)
    Schroeder, Thomas Michael
    Rautenberg, Christina
    Christopeit, Max
    Stelljes, Matthias
    Schmidt, Eva
    Groth, Christoph
    Scheid, Christoph
    Holtick, Udo
    Klein, Stefan A.
    Beelen, Dietrich W.
    Nachtkamp, Kathrin
    Haas, Rainer
    Germing, Ulrich
    Kroeger, Nicolaus
    Kobbe, Guido
    BLOOD, 2018, 132
  • [30] SIRPB1: BIOMARKER OF RESPONSE TO 5-AZACITIDINE TREATMENT IN MDS AND AML PATIENTS
    Guadagnuolo, V.
    Fontana, M. C.
    Papayannidis, C.
    Iacobucci, I.
    Padella, A.
    Simonetti, G.
    Imbrogno, E.
    Paolini, S.
    Abbenante, M.
    Parisi, S.
    Sartor, C.
    Ottaviani, E.
    Ferrari, A.
    Delledonne, M.
    Malagola, M.
    Fili, C.
    Russo, D.
    Cavo, M.
    Martinelli, G.
    HAEMATOLOGICA, 2015, 100 : 53 - 53
12345